Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
Elias Othman, Assistant Professor at Volgograd State Medical University, shared a post on LinkedIn:
“Can an enzyme involved in cell signaling become a target for antithrombotic drug discovery?
One of the research areas that has interested me is the search for new approaches to antithrombotic therapy.
We often think about thrombosis in terms of platelets and the coagulation cascade.
But drug discovery can also begin by asking a different question:
What intracellular pathways influence platelet function and thrombus formation?
One interesting target is glycogen synthase kinase-3 beta (GSK-3β), a multifunctional enzyme involved in several cellular signaling pathways.
In our research, we investigated 3-arylidene-2-oxindole derivatives as potential GSK-3β inhibitors and explored their antithrombotic properties.
What I find particularly interesting about this type of research is the journey:
- Molecular target
- Design and evaluation of compounds
- Pharmacological mechanism
- Effect on thrombosis
- Potential for future drug development
Of course, discovering a promising compound is only the beginning.
A finding from experimental research does not automatically mean that a new medicine is ready for patients.
There are many steps between target validation and clinical application.
That gap between a biological mechanism and a potential therapy is what makes drug discovery so fascinating to me.
What molecular target do you think has the most interesting potential for future antithrombotic drug development?”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera